Results 231 to 240 of about 1,949,693 (308)

Content Analysis of Responses From an INSAR Special Interest Group (SIG): Indigenous Perspectives on Autism

open access: yesAutism Research, EarlyView.
ABSTRACT Autism remains understudied and under‐detected in Indigenous communities across the globe. This content analysis investigates key themes and future directions for Indigenous autism research, as discussed during a Special Interest Group at the 2025 International Society for Autism Research meeting in Seattle, United States.
Grant Bruno   +5 more
wiley   +1 more source

A sustainable business ecosystem: a case study demonstrating biochar's potential

open access: yesBiofuels, Bioproducts and Biorefining, EarlyView.
Abstract The need for renewable, climate‐friendly resources has become urgent as legislators worldwide have sought to find ways to cut emissions while ensuring resource security for consumers. The use of biochar could help to achieve these goals. This study examines the current state of commercial biochar production and the maturity of the related ...
Kivijakola Juuso   +4 more
wiley   +1 more source

Switching disease‐modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
With multiple disease‐modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are driven by treatment burden, convenience, or adverse events.
Andrej Belančić   +4 more
wiley   +1 more source

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

Closing the gap: do we need a framework for embedding equity in health technology assessment? [PDF]

open access: yesInt J Technol Assess Health Care
Pearson-Stuttard J   +4 more
europepmc   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy